134 related articles for article (PubMed ID: 28807913)
1. Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats.
Hoover JL; Singley CM; Elefante P; DeMarsh P; Zalacain M; Rittenhouse S
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807913
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics/Pharmacodynamics of Peptide Deformylase Inhibitor GSK1322322 against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in Rodent Models of Infection.
Hoover J; Lewandowski T; Straub RJ; Novick SJ; DeMarsh P; Aubart K; Rittenhouse S; Zalacain M
Antimicrob Agents Chemother; 2016 Jan; 60(1):180-9. PubMed ID: 26482300
[TBL] [Abstract][Full Text] [Related]
3. Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae.
Min S; Ingraham K; Huang J; McCloskey L; Rilling S; Windau A; Pizzollo J; Butler D; Aubart K; Miller LA; Zalacain M; Holmes DJ; O'Dwyer K
Antimicrob Agents Chemother; 2015 Aug; 59(8):4644-52. PubMed ID: 26014938
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322.
O'Dwyer K; Hackel M; Hightower S; Hoban D; Bouchillon S; Qin D; Aubart K; Zalacain M; Butler D
Antimicrob Agents Chemother; 2013 May; 57(5):2333-42. PubMed ID: 23478958
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor.
Naderer OJ; Jones LS; Zhu J; Kurtinecz M; Dumont E
J Clin Pharmacol; 2013 Nov; 53(11):1168-76. PubMed ID: 23907665
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.
Naderer OJ; Dumont E; Zhu J; Kurtinecz M; Jones LS
J Antimicrob Chemother; 2013 Aug; 68(8):1901-9. PubMed ID: 23557930
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection.
Lewis RE; Klepser ME; Ernst EJ; Lund BC; Biedenbach DJ; Jones RN
Antimicrob Agents Chemother; 1999 Aug; 43(8):2005-9. PubMed ID: 10428927
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
Lepak AJ; Andes DR
Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
[TBL] [Abstract][Full Text] [Related]
11. Cellular pharmacokinetics and intracellular activity of the novel peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus laboratory and clinical strains with various resistance phenotypes: studies with human THP-1 monocytes and J774 murine macrophages.
Peyrusson F; Butler D; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2015 Sep; 59(9):5747-60. PubMed ID: 26169402
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling for concentration-dependent bactericidal activity of a bicyclolide, modithromycin.
Katsube T; Wajima T; Yamano Y; Yano Y
J Pharm Sci; 2014 Apr; 103(4):1288-97. PubMed ID: 24523230
[TBL] [Abstract][Full Text] [Related]
13. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
Naderer OJ; Dumont E; Zhu J; Kurtinecz M; Jones LS
Antimicrob Agents Chemother; 2013 May; 57(5):2005-9. PubMed ID: 23403431
[TBL] [Abstract][Full Text] [Related]
14. Potent sub-MIC effect of GSK1322322 and other peptide deformylase inhibitors on in vitro growth of Staphylococcus aureus.
Butler D; Chen D; O'Dwyer K; Lewandowski T; Aubart K; Zalacain M
Antimicrob Agents Chemother; 2014; 58(1):290-6. PubMed ID: 24165188
[TBL] [Abstract][Full Text] [Related]
15. Pharyngeal colonization and drug resistance profiles of Morraxella catarrrhalis, Streptococcus pneumoniae, Staphylococcus aureus, and Haemophilus influenzae among HIV infected children attending ART Clinic of Felegehiwot Referral Hospital, Ethiopia.
Mulu W; Yizengaw E; Alemu M; Mekonnen D; Hailu D; Ketemaw K; Abera B; Kibret M
PLoS One; 2018; 13(5):e0196722. PubMed ID: 29746496
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Doripenem in Pediatric Patients and Monte-Carlo Pharmacokinetic-Pharmacodynamic Simulations for Dosing Regimen Assessment.
Matsuo Y; Ishibashi T; Matsumoto S; Katsube T; Wajima T
J Pharm Sci; 2019 Sep; 108(9):3099-3105. PubMed ID: 30974120
[TBL] [Abstract][Full Text] [Related]
17. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor.
Ross JE; Scangarella-Oman NE; Miller LA; Sader HS; Jones RN
J Clin Microbiol; 2011 Nov; 49(11):3928-30. PubMed ID: 21918031
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.
Girard D; Finegan SM; Dunne MW; Lame ME
J Antimicrob Chemother; 2005 Aug; 56(2):365-71. PubMed ID: 16002421
[TBL] [Abstract][Full Text] [Related]
20. [Value of quantitative bacteriological examination of sputum in the evaluation of the effectiveness of chemotherapy of bacterial respiratory tract infections. I. Bacteriological studies].
Przybyłkiewicz Z; Nikodemowicz E; Kasprowicz A; Owsiński J
Pneumonol Pol; 1980 Aug; 48(8):535-43. PubMed ID: 6775309
[No Abstract] [Full Text] [Related]
[Next] [New Search]
